<
b>The
back cover picture shows
b> an e
bsulfur analogue that displays antifungal activity against various clinically relevant fungal
m>Candidam>
and m>Aspergillusm> strains, which are either equivalent or superior to the currently used antifungal drugs. The preli
minary antifungal
mechanis
m of action was deter
mined to
be correlated with an increase in reactive oxygen species. The safety of this e
bsulfur analogue co
mpound was evaluated
and found to
be co
mpara
ble with e
bselen, an analogous
molecule now in clinical trials, in ter
ms of
ma
mmalian toxicity. Overall, this work could potentially lead to develop
ment of new potent orally active antifungal agents to assist the current antifungal repertoire. More infor
mation can
be found in the Full Paper
by Sylvie Garneau-Tsodikova et al. on <
b>page 1507 in Issue 14, 2016
b> (DOI:
mdc.201600236" rel="references:http://dx.doi.org/10.1002/cmdc.201600236">10.1002/cmdc.201600236).